Sycamore nears a $9 billion Boots sale to the Weston family, about £6.8 billion at today's rate
The Wall Street Journal reports a deal could land within weeks. Converted, the price sits just under the £7 billion the two sides were discussing before the Westons cut their offer in the summer.
Sycamore Partners, the private equity firm that owns Walgreens, is close to selling the British pharmacy chain Boots to the Weston family for about $9 billion, Reuters reported on Wednesday, citing a Wall Street Journal story. The deal could be completed in the coming weeks if talks hold, according to the report. The Financial Times reported the same price and identified the buyer as Canada's Weston family.
Sycamore declined to comment and Boots did not immediately respond, Reuters said.
The number behind the number: the price barely moved
This sale looked in trouble in August. FashionNetwork, citing The Telegraph, reported then that the Westons had been discussing a £7 billion purchase, that they tabled a reduced offer after Australia's Sigma Healthcare walked away in June, and that Sycamore rejected it. A source put the odds of a deal at "50/50," and a stock market listing of Boots was floated as the alternative.
Put the new figure in pounds and the gap is small. At Wednesday afternoon's exchange rate of about $1.326 per pound, $9 billion is roughly £6.8 billion, about 3% under the £7 billion that was on the table before the summer. Going the other way, £7 billion would be worth about $9.3 billion today. Neither side has confirmed terms, and "about $9 billion" is a rounded reported number, so this is a comparison of approximate figures. But it suggests the two sides met close to the original number rather than at a steep discount.
What it means for Sycamore's Walgreens bet
Sycamore took Walgreens private in 2025. Reuters put that deal at about $10 billion; FashionNetwork cited $23.7 billion. The two numbers measure the deal differently, and the difference matters for how big a win Boots is. Against $10 billion, a $9 billion Boots sale equals about 90% of the headline price. Against $23.7 billion, it is about 38%.
Either way, Boots is the largest piece Sycamore can sell. According to the Journal's reporting relayed by Reuters, the firm split the company into five units to make non-core businesses easier to sell. Boots trades mainly in the UK and Ireland, with a Thai arm, Boots Opticians and the No7 beauty brand, FashionNetwork reported, while operations in Mexico and Germany may be separated.
Who it touches
Walgreens is no longer listed, so there is no US share price to move. The read-through is for traders watching private equity exits: a large retail carve-out closing near its pre-summer price is a data point in a year when, as we reported, seven IPOs were postponed in the third quarter, and after this very sale process stalled on price in August. For US Walgreens stores, suppliers and landlords, nothing changes with this deal; Boots is a separate British business.
Sources: Reuters, citing The Wall Street Journal; Financial Times; FashionNetwork, citing The Telegraph; exchange rate from Chronicle market data. This is market information, not investment advice.
Want your business to be the answer?
Get a full package of articles about your business, built so customers, Google and AI assistants can find you.
New ebook from The Company ChronicleHow to Research Like a Wall Street AnalystFind original sources, analyze trends, and build your own insights. 36 pages with worksheets.Get the ebook · $29Instant PDF download

